Plants metabolites as a prospective approach against the COVID-19
DOI:
https://doi.org/10.18203/2319-2003.ijbcp20211032Keywords:
Covid-19, Plant medicine, Drug targetsAbstract
The Coronavirus disease 2019 (COVID-19) caused by an RNA virus SARS-CoV-2 is an emerging global health pandemic. With currently no approved treatment or prophylaxis, the SARS-CoV-2 is rapidly transmitted via touch, droplets, and fomites. In most affected patients, the disease will have mild flu-like symptoms (fever, dry cough, and difficulty in breathing) and in selected patients may cause severe complications such as progressive pneumonia, acute respiratory distress syndrome, and organ failure due to hyper-inflammation and cytokine storm syndrome. Understanding the pathogenesis of the disease is essential for identification and rational design of effective drug targets. The plant metabolites can provide as a prospective approach for SARS-CoV-2, due to lowest possible side effect and antiviral properties. In this report, we provide an overview of the disease pathogenesis and highlight the potential therapeutic interventions.
References
Burke RM, Midgley CM, Dratch A, Fenstersheib M, Haupt T, Holshue M, et al. Active monitoring of persons exposed to patients with confirmed COVID-19 — United States, January–February 2020. MMWR Morb Mortal Wkly Rep. 2020.
Ong SWX, Tan YK, Chia PY, Lee TH, Ng OT, Wong MSY, et al. Air, Surface Environmental, and Personal Protective Equipment Contamination by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) From a Symptomatic Patient. JAMA. 2020;323(16):1610-12.
Lauer SA, Grantz KH, Bi Q, Jones FK, Zheng Q, Meredith HR, et al. The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application. Ann Intern Med. 2020;M20-0504.
Liu Y, Yan LM, Wan L, Xiang TX, Le A, Liu JM, et al. Viral dynamics in mild and severe cases of COVID-19. Lancet Infect Dis. 2020;20(6):656-57.
World Health Organization. WHO Director- General’s opening remarks at the media briefing on COVID-19 - 11 March 2020. WHO. https://www.who.int/dg/ speeches/detail/who- director- general- s- opening remarks-at- the- media- briefing- on- covid-19-11- march-2020. Last accessed on 3rd January, 2021.
Khan Z, Karataş Y, Rahman H. Anti COVID-19 drugs: need for more clinical evidence and global action. Adv Ther. 2020;37(6):2575-79.
CDC. Coronavirus Disease 2019 (COVID-19). Information for Clinicians on Investigational Therapeutics for Patients with COVID-19. Centers for Disease Control and Prevention. 2020. Available from https://www.cdc.gov/coronavirus/2019-ncov/hcp/therapeutic-options.html. Last accessed on 12 May, 2020.
Kirchdoerfer RN, Cottrell CA, Wang N, Pallesen J, Yassine HM, Turner HL et al. Pre-fusion structure of a human coronavirus spike protein. Nature. 2016;531(7592):118-21.
Gupta MK, Vemula S, Donde R, Gouda G, Behera L, Vadde R. In-silico approaches to detect inhibitors of the human severe acute respiratory syndrome coronavirus envelope protein ion channel. Journal of Biomolecular Structure and Dynamics. 2020;1-11.
Kumar S, Maurya VK, Prasad AK, Bhatt MLB, Saxena SK. Structural, glycosylation and antigenic variation between 2019 novel coronavirus (2019-nCoV) and SARS coronavirus (SARS-CoV). Virus disease. 2020;31(1):13-21.
Sarma P, Sekhar N, Prajapat M, Avti P, Kaur H, Kumar S et al. In-silico homology assisted identification of inhibitor of RNA binding against 2019-nCoV N-protein (N-terminal domain). Journal of Biomolecular Structure and Dynamics. 2020;1-9.
Coutard B, Valle C, de Lamballerie X, Canard B, Seidah NG, Decroly E. The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade. Antiviral Res. 2020;176: 104742.
Hemert VMJ, Worm VD, Knoops K, Mommaas AM, Gorbalenya AE, Snijder EJ. SARS-coronavirus replication/transcription complexes are membrane protected and need a host factor for activity in vitro. PLoS Pathogens. 2008;4(5):e1000054.
Valencia DN. Brief Review on COVID-19: The 2020 pandemic caused by SARS-CoV-2. Cureus. 2020;12(3):e7386
Belouzard S, Millet JK, Licitra BN, Whittaker GR. Mechanisms of coronavirus cell entry mediated by the viral spike protein. Viruses. 2012;4:1011-33.
Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271-280.
Andersen KG, Rambaut A, Lipkin WI, Holmes EC, Garry RF. The proximal origin of SARS-CoV- 2. Nature Medicine. 2020;26(4):450-452.
Wrapp D, Wang M, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020;10.
Harmer D, Gilbert M, Borman R, Clark KL. Quantitative RNA expression profiling of ACE2, a novel homologue of angiotensin converting enzyme. FEBS Letter. 2002;532(1-2):107-10.
Guo, Z. The modification of natural products for medical use. Acta Pharm Sin. 2017;7(2):119-36.
Newman DJ, Cragg GM. Natural Products as Sources of New Drugs over the Nearly Four Decades from 01/1981 to 09/2019. J Nat Prod. 2020;83(3):770-803.
Ganjhu RK, Mudgal PP, Maity H, Dowarha D, Devadiga S, Nag S, Arunkumar G. Herbal plants and plant preparations as remedial approach for viral diseases. Virus disease. 2015;26:225-36.
Utomo R.Y., Ikawati M., Meiyanto E. Revealing the Potency of Citrus and Galangal Constituents to Halt SARS-CoV-2 Infection. Preprints. 2020;214:1-8.
Islam MT, Sarkar C, El-Kersh DM, Jamaddar S, Uddin SJ, Shilpi JA et al. Natural products and their derivatives against coronavirus: A review of the non-clinical and pre-clinical data. Phytother. Res; 34(10):2471-2492.
Muchtaridi M, Fauzi M, Khairul Ikram NK, Mohd Gazzali A, Wahab HA. Natural Flavonoids as Potential Angiotensin-Converting Enzyme 2 Inhibitors for Anti-SARS-CoV-2. Molecules 2020; 25(17):3980.
Wu C, Liu Y, Yang Y, Zhang P, Zhong W, Wang Y, Wang Q, Xu Y, Li M, Li X, et al. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharm. Sin. B 2020; 10(5):766-788.
Sun X, Yau VK, Briggs B, Whittaker GR. Role of clathrin-mediated endocytosis during vesicular stomatitis virus entry into host cells. Virology. 2005;338:53-60.
Marsh M, Helenius A. Virus entry: open sesame. Cell. 2006;124:729-740.
Inoue Y, Tanaka N, Tanaka Y, Inoue S, Morita K, Zhuang M et al. Clathrin-dependent entry of severe acute respiratory syndrome coronavirus into target cells expressing ACE2 with the cytoplasmic tail deleted. J. Virol 2007; 81:8722–29.
Zhuang M, Jiang H, Suzuki Y, Li X, Xiao P, Tanaka T et al. Procyanidins and butanol extract of Cinnamomi Cortex inhibit SARS-CoV infection. Antiviral Res. 2009; 82(1):73-81.
Cinatl J, Morgenstern B, Bauer G. Glycyrrhizin, an active component of liquorice roots, and replication of SARS associated coronavirus. Lancet. 2003;361:2045-46.
Yu M, Lee J, Moo J. Identification of myricetin and scutellarein as novel chemical inhibitors of the SARS coronavirus helicase, nsP13. Bioorganic Med Chem Lett. 2020;22:4049-54.
Ryu YB, Jeong HJ, Kim JH. Biflavonoids from Torreya nucifera displaying SARS-CoV 3CLpro inhibition. Bioorganic Med Chem. 2010;18:7940-47.
Lin CW, Tsai FJ, Tsai CH. Anti-SARS coronavirus 3C-like protease effects of Isatis indigotica root and plant-derived phenolic compounds. Antivir Res. 2005;68:36-42.
